The East Asian Paradox: An Updated Position Statement on the Challenges to the Current Antithrombotic Strategy in Patients with Cardiovascular Disease

Hyun Kuk Kim; Udaya S. Tantry; Sidney C. Smith; Myung Ho Jeong; Seung Jung Park; Moo Hyun Kim; Do Sun Lim; Eun Seok Shin; Duk Woo Park; Yong Huo; Shao Liang Chen; Zheng Bo; Shinya Goto; Takeshi Kimura; Satoshi Yasuda; Wen Jone Chen; Mark Chan; Daniel Aradi; Tobias Geisler; Diana A. Gorog; Dirk Sibbing; Gregory Y.H. Lip; Dominick J. Angiolillo; Paul A. Gurbel; Young Hoon Jeong

doi:10.1055/s-0040-1718729

The East Asian Paradox: An Updated Position Statement on the Challenges to the Current Antithrombotic Strategy in Patients with Cardiovascular Disease

Hyun Kuk Kim, Udaya S. Tantry, Sidney C. Smith, Myung Ho Jeong, Seung Jung Park, Moo Hyun Kim, Do Sun Lim, Eun Seok Shin, Duk Woo Park, Yong Huo, Shao Liang Chen, Zheng Bo, Shinya Goto, Takeshi Kimura, Satoshi Yasuda, Wen Jone Chen, Mark Chan, Daniel Aradi, Tobias Geisler, Diana A. GorogDirk Sibbing, Gregory Y.H. Lip, Dominick J. Angiolillo, Paul A. Gurbel, Young Hoon Jeong

Research output: Contribution to journal › Review article › peer-review

124 Citations (Scopus)

Abstract

East Asian patients have reduced anti-ischemic benefits and increased bleeding risk during antithrombotic therapies compared with Caucasian patients. As potent P2Y 12 receptor inhibitors (e.g., ticagrelor and prasugrel) and direct oral anticoagulants are commonly used in current daily practice, the unique risk-benefit trade-off in East Asians has been a topic of emerging interest. In this article, we propose updated evidence and future directions of antithrombotic treatment in East Asian patients.

Original language	English
Pages (from-to)	422-432
Number of pages	11
Journal	Thrombosis and Haemostasis
Volume	121
Issue number	4
DOIs	https://doi.org/10.1055/s-0040-1718729
Publication status	Published - 2021 Apr 1
Externally published	Yes

Bibliographical note

Funding Information:
This study was supported by Basic Science Research Program through the National Research Foundation (NRF) of Korea funded by the Ministry of Science, ICT, and Future Planning (NRF-2015R1A5A2008833). The authors are solely responsible for the design and conduct of this review, the drafting, and editing of the manuscript, and its final contents.

Funding Information:
S.G. is a consultant for Janssen and Bristol-Myers Squibb. S.G. received research grant from Sanofi, Pfizer, and Ono, and independent research grant support from Bristol-Myers Squibb (33999603). S.G. also received personal fee from Thrombosis Research Institute (London, United Kingdom) as a member of Steering Committee for GARFIELD-AF and GARFIELD-VTE and from the American Heart Association as an associate editor. T.G. research is funded by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) TRR 240 “Platelets—Molecular, Cellular and Systemic Functions in Health and Disease” (Project number 374031971). T.G. received personal fees from Astra Zeneca, Boehringer Ingelheim, Chiesi, Ferrer, and Pfizer, and research grants and personal fees from Bayer Healthcare, Bristol-Myers Squibb, Daiichi Sankyo, and Eli Lilly. D.A.G. reports institutional grants from Bayer and BMS, and speaker fees from Bayer and AstraZeneca. G.Y.H. is a consultant for Bayer/Janssen, BMS/Pfizer, Medtronic, Boehringer Ingelheim, Novartis, Verseon, and Daiichi-Sankyo; speaker for Bayer, BMS/ Pfizer, Medtronic, Boehringer Ingelheim, and Daiichi-Sankyo. No fees were directly received personally. D.A.J. has received consulting fees or honoraria from Amgen, Aralez, AstraZeneca, Bayer, Biosensors, Boehringer Ingel-heim, Bristol-Myers Squibb, Chiesi, Daiichi-Sankyo, Eli Lilly, Haemonetics, Janssen, Merck, PhaseBio, PLx Pharma, Pfizer, Sanofi, and The Medicines Company, and has received payments for participation in review activities from CeloNova and St. Jude Medical. He also declares that his institution has received research grants from Amgen, AstraZeneca, Bayer, Biosensors, CeloNova, CSL Behring, Daiichi-Sankyo, Eisai, Eli Lilly, Gilead, Janssen, Matsutani Chemical Industry Co., Merck, Novartis, Osprey Medical, Renal Guard Solutions, and the Scott R. MacKenzie Foundation. G.P.A.G. reports serving as a consultant and receiving fees/honoraria from Daiichi Sankyo, Bayer, AstraZeneca, Merck, Boehringer, New Haven Pharmaceuticals, Janssen, and CSL, and receiving grants from the National Institutes of Health, Daiichi Sankyo, CSL, Astra-Zeneca, Harvard Clinical Research Institute, Haemonetics, New Haven Pharmaceuticals, Duke Clinical Research Institute, Sinnowa, and Coramed. P.A.G. has patents in the field of platelet function testing. M.H.J. has received honoraria for lectures from AstraZeneca, Sanofi-Aventis, Daiichi Sankyo/Lilly, Haemonetics, Otsuka, Han-mi Pharmaceuticals, and Yuhan Pharmaceuticals, and research grants or support from AstraZeneca, Korean Society of Interventional Cardiology, Han-mi Pharmaceuticals, Yuhan Pharmaceuticals, Otsuka, and Haemonetics. The other authors report no conflicts of interest.

Publisher Copyright:
© 2020. Thieme. All rights reserved.

Keywords

antiplatelet therapy
bleeding risk
direct oral anticoagulants
ischemic risk
race

ASJC Scopus subject areas

Hematology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1055/s-0040-1718729

Cite this

Kim, H. K., Tantry, U. S., Smith, S. C., Jeong, M. H., Park, S. J., Kim, M. H., Lim, D. S., Shin, E. S., Park, D. W., Huo, Y., Chen, S. L., Bo, Z., Goto, S., Kimura, T., Yasuda, S., Chen, W. J., Chan, M., Aradi, D., Geisler, T., ... Jeong, Y. H. (2021). The East Asian Paradox: An Updated Position Statement on the Challenges to the Current Antithrombotic Strategy in Patients with Cardiovascular Disease. Thrombosis and Haemostasis, 121(4), 422-432. https://doi.org/10.1055/s-0040-1718729

Kim, HK, Tantry, US, Smith, SC, Jeong, MH, Park, SJ, Kim, MH, Lim, DS, Shin, ES, Park, DW, Huo, Y, Chen, SL, Bo, Z, Goto, S, Kimura, T, Yasuda, S, Chen, WJ, Chan, M, Aradi, D, Geisler, T, Gorog, DA, Sibbing, D, Lip, GYH, Angiolillo, DJ, Gurbel, PA & Jeong, YH 2021, 'The East Asian Paradox: An Updated Position Statement on the Challenges to the Current Antithrombotic Strategy in Patients with Cardiovascular Disease', Thrombosis and Haemostasis, vol. 121, no. 4, pp. 422-432. https://doi.org/10.1055/s-0040-1718729

@article{2142498c150b4713a81d45dcc3ab4b24,

title = "The East Asian Paradox: An Updated Position Statement on the Challenges to the Current Antithrombotic Strategy in Patients with Cardiovascular Disease",

abstract = "East Asian patients have reduced anti-ischemic benefits and increased bleeding risk during antithrombotic therapies compared with Caucasian patients. As potent P2Y 12 receptor inhibitors (e.g., ticagrelor and prasugrel) and direct oral anticoagulants are commonly used in current daily practice, the unique risk-benefit trade-off in East Asians has been a topic of emerging interest. In this article, we propose updated evidence and future directions of antithrombotic treatment in East Asian patients.",

keywords = "antiplatelet therapy, bleeding risk, direct oral anticoagulants, ischemic risk, race",

author = "Kim, {Hyun Kuk} and Tantry, {Udaya S.} and Smith, {Sidney C.} and Jeong, {Myung Ho} and Park, {Seung Jung} and Kim, {Moo Hyun} and Lim, {Do Sun} and Shin, {Eun Seok} and Park, {Duk Woo} and Yong Huo and Chen, {Shao Liang} and Zheng Bo and Shinya Goto and Takeshi Kimura and Satoshi Yasuda and Chen, {Wen Jone} and Mark Chan and Daniel Aradi and Tobias Geisler and Gorog, {Diana A.} and Dirk Sibbing and Lip, {Gregory Y.H.} and Angiolillo, {Dominick J.} and Gurbel, {Paul A.} and Jeong, {Young Hoon}",

note = "Funding Information: This study was supported by Basic Science Research Program through the National Research Foundation (NRF) of Korea funded by the Ministry of Science, ICT, and Future Planning (NRF-2015R1A5A2008833). The authors are solely responsible for the design and conduct of this review, the drafting, and editing of the manuscript, and its final contents. Funding Information: S.G. is a consultant for Janssen and Bristol-Myers Squibb. S.G. received research grant from Sanofi, Pfizer, and Ono, and independent research grant support from Bristol-Myers Squibb (33999603). S.G. also received personal fee from Thrombosis Research Institute (London, United Kingdom) as a member of Steering Committee for GARFIELD-AF and GARFIELD-VTE and from the American Heart Association as an associate editor. T.G. research is funded by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) TRR 240 “Platelets—Molecular, Cellular and Systemic Functions in Health and Disease” (Project number 374031971). T.G. received personal fees from Astra Zeneca, Boehringer Ingelheim, Chiesi, Ferrer, and Pfizer, and research grants and personal fees from Bayer Healthcare, Bristol-Myers Squibb, Daiichi Sankyo, and Eli Lilly. D.A.G. reports institutional grants from Bayer and BMS, and speaker fees from Bayer and AstraZeneca. G.Y.H. is a consultant for Bayer/Janssen, BMS/Pfizer, Medtronic, Boehringer Ingelheim, Novartis, Verseon, and Daiichi-Sankyo; speaker for Bayer, BMS/ Pfizer, Medtronic, Boehringer Ingelheim, and Daiichi-Sankyo. No fees were directly received personally. D.A.J. has received consulting fees or honoraria from Amgen, Aralez, AstraZeneca, Bayer, Biosensors, Boehringer Ingel-heim, Bristol-Myers Squibb, Chiesi, Daiichi-Sankyo, Eli Lilly, Haemonetics, Janssen, Merck, PhaseBio, PLx Pharma, Pfizer, Sanofi, and The Medicines Company, and has received payments for participation in review activities from CeloNova and St. Jude Medical. He also declares that his institution has received research grants from Amgen, AstraZeneca, Bayer, Biosensors, CeloNova, CSL Behring, Daiichi-Sankyo, Eisai, Eli Lilly, Gilead, Janssen, Matsutani Chemical Industry Co., Merck, Novartis, Osprey Medical, Renal Guard Solutions, and the Scott R. MacKenzie Foundation. G.P.A.G. reports serving as a consultant and receiving fees/honoraria from Daiichi Sankyo, Bayer, AstraZeneca, Merck, Boehringer, New Haven Pharmaceuticals, Janssen, and CSL, and receiving grants from the National Institutes of Health, Daiichi Sankyo, CSL, Astra-Zeneca, Harvard Clinical Research Institute, Haemonetics, New Haven Pharmaceuticals, Duke Clinical Research Institute, Sinnowa, and Coramed. P.A.G. has patents in the field of platelet function testing. M.H.J. has received honoraria for lectures from AstraZeneca, Sanofi-Aventis, Daiichi Sankyo/Lilly, Haemonetics, Otsuka, Han-mi Pharmaceuticals, and Yuhan Pharmaceuticals, and research grants or support from AstraZeneca, Korean Society of Interventional Cardiology, Han-mi Pharmaceuticals, Yuhan Pharmaceuticals, Otsuka, and Haemonetics. The other authors report no conflicts of interest. Publisher Copyright: {\textcopyright} 2020. Thieme. All rights reserved.",

year = "2021",

month = apr,

day = "1",

doi = "10.1055/s-0040-1718729",

language = "English",

volume = "121",

pages = "422--432",

journal = "Thrombosis and Haemostasis",

issn = "0340-6245",

publisher = "Schattauer GmbH",

number = "4",

}

TY - JOUR

T1 - The East Asian Paradox

T2 - An Updated Position Statement on the Challenges to the Current Antithrombotic Strategy in Patients with Cardiovascular Disease

AU - Kim, Hyun Kuk

AU - Tantry, Udaya S.

AU - Smith, Sidney C.

AU - Jeong, Myung Ho

AU - Park, Seung Jung

AU - Kim, Moo Hyun

AU - Lim, Do Sun

AU - Shin, Eun Seok

AU - Park, Duk Woo

AU - Huo, Yong

AU - Chen, Shao Liang

AU - Bo, Zheng

AU - Goto, Shinya

AU - Kimura, Takeshi

AU - Yasuda, Satoshi

AU - Chen, Wen Jone

AU - Chan, Mark

AU - Aradi, Daniel

AU - Geisler, Tobias

AU - Gorog, Diana A.

AU - Sibbing, Dirk

AU - Lip, Gregory Y.H.

AU - Angiolillo, Dominick J.

AU - Gurbel, Paul A.

AU - Jeong, Young Hoon

N1 - Funding Information: This study was supported by Basic Science Research Program through the National Research Foundation (NRF) of Korea funded by the Ministry of Science, ICT, and Future Planning (NRF-2015R1A5A2008833). The authors are solely responsible for the design and conduct of this review, the drafting, and editing of the manuscript, and its final contents. Funding Information: S.G. is a consultant for Janssen and Bristol-Myers Squibb. S.G. received research grant from Sanofi, Pfizer, and Ono, and independent research grant support from Bristol-Myers Squibb (33999603). S.G. also received personal fee from Thrombosis Research Institute (London, United Kingdom) as a member of Steering Committee for GARFIELD-AF and GARFIELD-VTE and from the American Heart Association as an associate editor. T.G. research is funded by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) TRR 240 “Platelets—Molecular, Cellular and Systemic Functions in Health and Disease” (Project number 374031971). T.G. received personal fees from Astra Zeneca, Boehringer Ingelheim, Chiesi, Ferrer, and Pfizer, and research grants and personal fees from Bayer Healthcare, Bristol-Myers Squibb, Daiichi Sankyo, and Eli Lilly. D.A.G. reports institutional grants from Bayer and BMS, and speaker fees from Bayer and AstraZeneca. G.Y.H. is a consultant for Bayer/Janssen, BMS/Pfizer, Medtronic, Boehringer Ingelheim, Novartis, Verseon, and Daiichi-Sankyo; speaker for Bayer, BMS/ Pfizer, Medtronic, Boehringer Ingelheim, and Daiichi-Sankyo. No fees were directly received personally. D.A.J. has received consulting fees or honoraria from Amgen, Aralez, AstraZeneca, Bayer, Biosensors, Boehringer Ingel-heim, Bristol-Myers Squibb, Chiesi, Daiichi-Sankyo, Eli Lilly, Haemonetics, Janssen, Merck, PhaseBio, PLx Pharma, Pfizer, Sanofi, and The Medicines Company, and has received payments for participation in review activities from CeloNova and St. Jude Medical. He also declares that his institution has received research grants from Amgen, AstraZeneca, Bayer, Biosensors, CeloNova, CSL Behring, Daiichi-Sankyo, Eisai, Eli Lilly, Gilead, Janssen, Matsutani Chemical Industry Co., Merck, Novartis, Osprey Medical, Renal Guard Solutions, and the Scott R. MacKenzie Foundation. G.P.A.G. reports serving as a consultant and receiving fees/honoraria from Daiichi Sankyo, Bayer, AstraZeneca, Merck, Boehringer, New Haven Pharmaceuticals, Janssen, and CSL, and receiving grants from the National Institutes of Health, Daiichi Sankyo, CSL, Astra-Zeneca, Harvard Clinical Research Institute, Haemonetics, New Haven Pharmaceuticals, Duke Clinical Research Institute, Sinnowa, and Coramed. P.A.G. has patents in the field of platelet function testing. M.H.J. has received honoraria for lectures from AstraZeneca, Sanofi-Aventis, Daiichi Sankyo/Lilly, Haemonetics, Otsuka, Han-mi Pharmaceuticals, and Yuhan Pharmaceuticals, and research grants or support from AstraZeneca, Korean Society of Interventional Cardiology, Han-mi Pharmaceuticals, Yuhan Pharmaceuticals, Otsuka, and Haemonetics. The other authors report no conflicts of interest. Publisher Copyright: © 2020. Thieme. All rights reserved.

PY - 2021/4/1

Y1 - 2021/4/1

N2 - East Asian patients have reduced anti-ischemic benefits and increased bleeding risk during antithrombotic therapies compared with Caucasian patients. As potent P2Y 12 receptor inhibitors (e.g., ticagrelor and prasugrel) and direct oral anticoagulants are commonly used in current daily practice, the unique risk-benefit trade-off in East Asians has been a topic of emerging interest. In this article, we propose updated evidence and future directions of antithrombotic treatment in East Asian patients.

AB - East Asian patients have reduced anti-ischemic benefits and increased bleeding risk during antithrombotic therapies compared with Caucasian patients. As potent P2Y 12 receptor inhibitors (e.g., ticagrelor and prasugrel) and direct oral anticoagulants are commonly used in current daily practice, the unique risk-benefit trade-off in East Asians has been a topic of emerging interest. In this article, we propose updated evidence and future directions of antithrombotic treatment in East Asian patients.

KW - antiplatelet therapy

KW - bleeding risk

KW - direct oral anticoagulants

KW - ischemic risk

KW - race

UR - http://www.scopus.com/inward/record.url?scp=85096095586&partnerID=8YFLogxK

U2 - 10.1055/s-0040-1718729

DO - 10.1055/s-0040-1718729

M3 - Review article

C2 - 33171520

AN - SCOPUS:85096095586

SN - 0340-6245

VL - 121

SP - 422

EP - 432

JO - Thrombosis and Haemostasis

JF - Thrombosis and Haemostasis

IS - 4

ER -

The East Asian Paradox: An Updated Position Statement on the Challenges to the Current Antithrombotic Strategy in Patients with Cardiovascular Disease

Abstract

Bibliographical note

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this